Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

756 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-22

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rhinitis, or inflammation of the nasal mucosa, can present with nasal obstruction, nasal discharge, itch or sneezing. If the sinusal mucosa is involved as well, it is called rhinosinusitis and facial pain or loss of smell is possible. Several causes are known, such as an underlying allergy ("allergic rhinitis", AR). If at least 2 symptoms are present for at least 12 weeks, it is called "chronic rhinosinusitis" (CRS).

Up to 2/3 of the AR and CRS patients have symptoms upon exposure to triggers such as sudden temperature changes, smoke, fragrances… a phenomenon called "nasal hyperreactivity" (NHR). It is currently not clear why some patients suffer NHR while others do not.

In this study, the investigators want to determine the prevalence and severity of nasal hyperreactivity in patients with chronic upper airway inflammation. To this end, patients and healthy controls will be asked to fill out a questionnaire inquiring presence and severity of nasal symptoms upon exposure to particular environmental triggers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Epidemiological and Intrinsic Characteristics of Chronic Rhinitis

NCT06370468

Chronic Rhinitis

RECRUITING

Upper Airway Inflammation and Olfaction: Mechanisms of Loss and Recovery

NCT06776042

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

RECRUITING NA

An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms

NCT01553110

Acute Rhinosinusitis Allergic Rhinitis

COMPLETED

Immunologic Aspects of the Pathogenesis of Chronic Sinusitis in Children

NCT00004638

Sinusitis

COMPLETED NA

Neuro-immunological Analysis of Idiopathic Rhinitis Patients and Controls Treated With Capsaicin.

NCT01223820

Idiopathic Rhinitis Patients Healthy Controls

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperactivity Chronic Rhinosinusitis (Diagnosis) Chronic Rhinitis Upper Respiratory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Patients with chronic upper airway inflammation

Questionnaire

Intervention Type OTHER

Patients and healthy controls will fill out a questionnaire

Healthy control

Healthy controls without chronic upper airway inflammation

Questionnaire

Intervention Type OTHER

Patients and healthy controls will fill out a questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

Patients and healthy controls will fill out a questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-65 y
* Nasal inflammatory symptoms for 12 weeks or longer (nasal obstruction, post-nasal drip, rhinorrhea, loss of smell, sneezing/itch, facial pain)
* Signed informed consent

* age 18-65 y
* No nasal inflammatory symptoms for 12 weeks or longer (nasal obstruction, post-nasal drip, rhinorrhea, loss of smell, sneezing/itch, facial pain)
* Signed informed consent